Clinical trials: Hemostatic Agents
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This is a single-center, open clinical study, divided into two phases of dose escalation and dose expansion, to observe the safety and efficacy of RD140 injection at different doses in patients with relapsed/refractory multiple…
- Trial name
- NCT06655519
- Testing
- CAR-T（RD140 injection）
- Volunteers
- 12 people
- Sponsor
- Peking University People's Hospital
Caregivers of Patients With Multiple Myeloma
Quality of Life Assessment of Caregivers of Patients With Multiple Myeloma
The diagnosis and treatment of multiple myeloma affect not only the patient but also their family and caregivers. Advances in therapy have transformed the follow-up of patients treated for multiple myeloma.
- Trial name
- ENTRAIDANT (NCT07276230)
- Testing
- Therapeutic Education and Needs Assessment Program for Caregivers
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coagulopathy in Patients Having Thoraco-Abdominal Aneurysm Repair
Fibrinogen as an Alternative to FFP in Aortic Surgery.
Thoracoabdominal aneurysm (TAAA) repair is a major elective vascular operation associated with a large blood loss and potentially life-threatening clotting abnormalities.
- Trial name
- NCT00994045
- Testing
- Fibrinogen concentrate, Fresh Frozen Plasma
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- University of Edinburgh
Mucositis, Multiple Myeloma
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
This is a pilot study to explore and identify changes in molecular processes within the oral mucosa that are associated with the development of oral mucositis (OM) in patients treated with Melphalan who undergo autologous…
- Conditions
- Mucositis, Multiple Myeloma, Amyloidosis, Oral Mucositis
- Trial name
- NCT02589860
- Testing
- Melphalan kinetic study, Oral bacterial study, Gene expression study
- Where
- 2 sites in United States
- Sponsor
- Sherif S. Farag
Multiple Myeloma and Plasma Cell Neoplasm
Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00941720
- Testing
- busulfan, cyclophosphamide, autologous hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Total Marrow Irradiation for Refractory Acute Leukemia
RATIONALE: Giving chemotherapy and total marrow irradiation before a donor umbilical cord blood or hematopoietic stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT00686556
- Testing
- cyclophosphamide, cyclosporine, Fludarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS
This protocol is a phase III multicenter, randomized, controlled study designed to assess the safety and the efficacy of standard schedule versus a new algoritm of dose reductions in elderly and unfit newly diagnosed Multiple…
- Trial name
- NCT02215980
- Testing
- Lenalidomide, Dexamethasone
- Where
- Italy
- Volunteers
- 210 people
- Sponsor
- Fondazione EMN Italy Onlus
Multiple Myeloma and Plasma Cell Neoplasm
CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00558896
- Testing
- dexamethasone, pomalidomide
- Where
- 3 sites in United States
- Volunteers
- 378 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Development of a Standardized Reference Guide for Tuning Adherence to Dispense During a Initial Pharmaceutical Consulting (CP ) to the Patient With Multiple Myeloma Oral Chemotherapy Primocure
The hypothesis is that the implementation of an initial Pharmaceutical Consultation (PC) program based on the provision of standardized information to patients treated for multiple myeloma as a first course of chemotherapy, could…
- Trial name
- NCT04045561
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Refractory Multiple Myeloma
Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy
This phase II trial studies how well carfilzomib works in treating patients with multiple myeloma in first relapse or refractory to first-line therapy.
- Trial name
- NCT02020941
- Testing
- carfilzomib, dexamethasone, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Attaya Suvannasankha
Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)
Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery
The treatment of colorectal cancer, in the absence of metastases, is primarily based on surgical removal. Colorectal surgery, which involves resecting part of the intestine and restoring intestinal continuity, carries a risk of…
- Trial name
- POSBIO-CRC (NCT07268846)
- Testing
- Postbiotic
- Where
- Brazil
- Volunteers
- 164 people
- Sponsor
- AC Camargo Cancer Center
Multiple Myeloma
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
- Trial name
- MajesTEC-2 (NCT04722146)
- Testing
- Teclistamab, Daratumumab, Pomalidomide
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 140 people
- Sponsor
- Janssen Research & Development, LLC
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia (PCL)
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
This is an open-label, single-arm, Phase 2 study to evaluate the efficacy and safety of IL-15-armored chimeric antigen receptor T-cell (CAR-T) therapy in subjects with relapsed or refractory multiple myeloma and plasma cell…
- Trial name
- NCT07509086
- Testing
- IL-15-armored CAR-T cells
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Hospital of Jilin University
Myeloma Multiple
Bioequivalence Studies of Dasatinib 100 Mg
A bioequivalence study of Dasatinib will be carried out in 46 healthy subjects, in fed condition, following the complete replicated design, randomized, comparative of 2 sequences, 2 study formulations, in a single dose of 100 mg…
- Trial name
- BE-Dasatinib (NCT05944783)
- Testing
- Dasatinib 100 MG
- Where
- Colombia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Centro de Atencion e Investigacion Medica
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Advanced Solid Tumors, Multiple Myeloma
A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
This study will determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) of single agent ONC201 in patients with advanced solid tumors or multiple myeloma.
- Trial name
- NCT02609230
- Testing
- ONC-201
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Fox Chase Cancer Center
Exercise Behavior, Multiple Myeloma
Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma (MM-Exercise)
MM-Exercise is a prospective, single-centre, observational pilot study of patients with newly diagnosed multiple myeloma who have not yet started chemotherapy and whose resting echocardiogram is unremarkable or only mildly…
- Trial name
- MM-Exercise (NCT07851493)
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Technical University of Munich
Multiple Myeloma
Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients
The aim of this non-interventional study is to collect primarily the percentage of patients who receive the full dose of dexamethasone (20 or 40 mg orally once daily on days 1, 8, 15 and 22 of the repetitive 28-day cycles, 20 mg…
- Trial name
- NCT03001804
- Where
- 12 sites in Austria
- Volunteers
- 29 people
- Sponsor
- Celgene
Hypofibrinogenemia, Afibrinogenemia
Human Fibrinogen Concentrate in Pediatric Cardiac Surgery
The goal of the study is to determine whether the use of Human Fibrinogen Concentrate (RiaSTAP) will decrease blood loss and the need for component blood therapy in neonates and infants undergoing cardiopulmonary bypass.
- Conditions
- Hypofibrinogenemia, Afibrinogenemia, Bleeding Disorders
- Trial name
- RiaSTAP (NCT02822599)
- Testing
- RiaStAP, Saline
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Multiple Myeloma
Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma
This is a research study for newly diagnosed multiple myeloma or multiple myeloma has returned (relapsed). Multiple myeloma is a type of cancer that begins in white blood cells called plasma cells.
- Trial name
- NCT01142232
- Testing
- Lenalidomide plus Melphalan during autologous stem cell transplantation, Lenalidomide maintenance
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Attaya Suvannasankha
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.